During autumn last year, the World Health Organization (WHO) announced that a vaccine to prevent dengue fever was available for people across the world aged 9 to 16 years old. This should have been exceptionally welcome news in Indonesia, where dengue has affected more than 120,000 people at a cost of roughly US$323 million annually, according to the Indonesian Technical Advisory Group on Immunization.
Accordingly, last September, Indonesia's Food and Drug Monitoring Agency approved the dengue vaccine, making it widely available in the private market.
Unfortunately, Indonesia continues to see its national coverage rates below the global average. Its vaccine delivery system has been plagued by several major hurdles including a strain...
Starting from IDR 55,000/month
Disclaimer: The opinions expressed in this article are those of the author and do not reflect the official stance of The Jakarta Post.